1. Introduction
===============

Pharmacopuncture is a new-typed acupuncture treatment to combine merits of acupuncture and herbal medicine and one of the most broadly used treatments in traditional Korean doctors (TKM) because of usefulness ([@b1-kpi-21-104]). The diverse types of pharmcopuncture have been developed such as eight principle pharmacopuncuture, meridian field pharmacopuncture, mountain ginseng pharmacopuncture (MGP), animal based pharmacopuncture, and pharmacopuncture for blood and qi recuperation and so on ([@b1-kpi-21-104], [@b2-kpi-21-104]).

Danggui (DG) belongs to a member of the Apiaceae family. The kinds of DG include Angelica gigas Nakai (AGN) in Korea, Angelica sinensis(Oliv.) Diels in China and Angelica acutiloba Kitag. in Japan. AGN is called Cham Dang Gui, namely Korean DG. The root of AGN, namely Angelica gigas radix (AGR), has been used to treat in Korea ([@b3-kpi-21-104], [@b4-kpi-21-104]). DG is called 'female ginseng' because DG has effect to tonify blood and has been used to treat many female diseases cause by blood deficiency ([@b5-kpi-21-104], [@b6-kpi-21-104]). In Dong-Ui-Bo-Gam, DG is major component medicinal herb among formulas used to treat female diseases related to menstruation, pregnancy and delivery, and postpartum disease ([@b3-kpi-21-104]). The effects of DG have reported to have anti-inflammation ([@b7-kpi-21-104], [@b8-kpi-21-104]), anti-platelet ([@b9-kpi-21-104]), anti-cancer ([@b10-kpi-21-104]), memory improvement ([@b11-kpi-21-104]), anti-bacteria ([@b12-kpi-21-104]), immune stimulation ([@b13-kpi-21-104]), anti-diabetics ([@b14-kpi-21-104]), and liver protection ([@b15-kpi-21-104]). DG contains fat-soluble ingredients, essential oil, and water-soluble ingredients (polysaccharide). Fat-soluble ingredients, such as decursin, decusinol angelate, umbelliferone and so on, account for large portion of DG ingredients and are one of main components that indicate a treatment effects ([@b16-kpi-21-104]).

Danggui pharmacopuncture (DGP) is the water-soluble pharmacopuncture, which makes fat-soluble ingredient and essential oil to dissolve in water. So active components of water-soluble DGP (WDP) can absorb the body easily and can represent good effects ([@b4-kpi-21-104]). The original pharmacopuncture is put on meridian points so they are either hypodermic or intramuscular injections. However, intravenously injecting pharmacopuncture increases the effectiveness of pharmacopuncture and will increase the application of diseases. Wild ginseng pharmacopuncture is being applied as intravenous injections as it preserves energy and various studies are being conducted on intravenous injections ([@b2-kpi-21-104], [@b17-kpi-21-104]--[@b19-kpi-21-104]).

The studies on intravenous injections of WDP have not been reported except for neuroprotective effect ([@b20-kpi-21-104]). Therefore, further research needs to be conducted. Intravenous injections can increase the effects of WDP but as it is processed right into the body without detoxification, safety is the most important aspect. Although there have reports assuring health safety in single toxicity tests for muscles ([@b4-kpi-21-104]), but there haven't been any safety reports regarding intravenous injections. Therefore, intravenous injection toxicity tests are necessary.

The aim of the study is to investigate toxicity reaction of WDP intravenous administration and lethal dose by using male and female Sprague-Dawley rats.

2. Materials and Methods
========================

For WDP preparation, Korean angelica extraction was obtained by filtering grinded Korean angelica root 1 kg that was mixed at 80 rpm with 70% ethanol 5 L, during 6 hours at 60°C. Then Angelica extraction 5 kg (extract + extract solvent) was condensed to 370 g Angelica concentration that included decursin and decursinol angelate. The Angelica extract and an emulsifier were quantified to the reaction beaker. To make water-soluble, WFI (Water for Injection-Fine FA, Korea) was added to the beaker and stir by high speed stirrer. Water solution was adjusted to pH 7.3 by NaOH solution. A filter (1 μm, satorius) equipment was set up between preparation tank and filling tank and emulsified solution was transferred to filling tank by N2 gas. After fractioning in the sterilized vial bottle, the bottle was kept refrigerated at 4°C after autoclaving 30 minutes at 121°C in the low temperature sterilizer (high pressure sterilizer, fine FA, KOREA).

In the study, Sprague-Dawley rats (ORIENTBIO INC., Korea) were used. When taking-in, visual inspection and weight measurement of the rats by electronic scale (CP3202S, Sartorius, Germany) were performed. during 7-day adaptation period, general symptoms were examined every day. To fetch animals, rats were transferred from quarantine to the animal room after observing general symptoms for 3 days. At the end of the adaptation day, weights were measured, and general symptoms were checked to confirm normality. At the time of IV injection, weight range of 6-week rats were 191.2 \~ 212.9 g males and 148.9 \~ 167.2 g females, 20 rats each. The raise condition were as follows: temperature 21.0 \~ 22.9°C, ventilation frequency 10 \~ 15 time/hour, relative humidity 43.2 \~ 59.6%, lighting time 12 hour/day (7:00--19:00), and illumination intensity 150 \~ 300 Lux. Rats were allowed to free intake of Telkad Certified Irradiated Global 18% Protein Rodent Diet 2918C (Harlan Laboratories, INC., USA) solid feed from the feeding system.

The study was approved by the approval of the Institutional Animal Care and Use Committee according to Laboratory Animal Act in Biotoxtech Co. (Approval No: 130366). The study was followed by Good Laboratory Practice regulation (Ministry of Food and Drug Safety notification; MFDSn) and performed by Standard for Toxicity Study of Pharmaceuticals (MFDSn).

Groups were separated at the end of the adaptation day. At the group separation day, 20 males and 20 females rats that approximate mean weight, were selected. Selected animals were randomized into 4 groups to have equal mean weight, 5 rats per each group ([Table 1](#t1-kpi-21-104){ref-type="table"}). During observation period, individuals were marked at the tail of the rats with blue oil-based pen, and color individual identification cards were attached at the breeding cage.

As clinical application route will be intravenous, WDP was injected intravenously. Injection doses were 0.5 mL/animal for control and high-dose group, 0.125 mL/animal for low-dose group, and 0.25 mL/animal for middle-dose group ([Table 1](#t1-kpi-21-104){ref-type="table"}). The solutions were injected once at a speed of approximately 2 mL/min at the tail vein with a disposable syringe (1 mL, 26G). The scheduled WDP clinical dose is 1.0 mL/time.

The pilot test of the study (Biotoxtech Study No.: B13480P) that single dose IV injection to the male and female rats of 0.5 mL/animal, did not reported death case. Based on the pilot test results and discussion with the sponsor, the administration dose of the study was set to 0.5 mL/animal high-dose, and applied at the ratio of 2 for middle-dose and low-dose, 0.25 and 0.125 mL/animal, respectively. The same dose of high-dose group of normal saline was administrated to the control group.

At the injection day (day 0), general conditions (toxicity symptom types, onset time, recovery time, etc.) and death were observed 30 minutes, 1 hour, 2hour, 4 hour and 6 hour after the injection. General symptoms were observed daily during injection day 1 to day 14. Weights were measured at injection day (before the injection), 3, 7, and 14 days after the injection.

All animals were fasted more than 18 hours before the autopsy for hematological test. At the autopsy day (15 days after the administration), animals were anesthetized with isoflurane and blood was gathered from the abdominal aorta. Blood 1 mL was collected in the EDTA tube to analyze by the blood corpuscle analyzer (ADVIA 120, SIEMENS, Germany). Erythrocyte count (RBC), hematocrit (HCT), hemoglobin (HGB), mean corpuscular hemoglobin (MCH), mean corpuscular hemoglobin concentration (MCHC), mean corpuscular volume (MCV), platelet (PLT), leucocyte count (WBC), neutrophils (NEU), eosinophils (EOS), basophils (BASO), reticulocytes (Reti), lymphocytes (LYM), monocytes (MONO) were measured.

For blood coagulation test, blood plasma was taken by following methods: collected blood 2 mL were kept in the 3.2% sodium citrate tube, followed by 3,000 rpm centrifuge for 10 minutes. Prothrombin time (PT) and activated partial thromboplastin time (aPTT) were checked by the coagulation time analyzer (Coapresta 2000, SEKISUI, Japan).

For blood biochemical examination, the remained blood collected from the abdominal aorta was centrifuged by 3,000 rpm for 10 minutes to get blood serum. Blood biochemical analyzer (7180, HITACHI, Japan) were applied to analyze alanine aminotransferase (ALT), aspartate aminotransferase (AST), alkaline phosphatase (ALP), g amma glutamyl transpeptidase (γ-GTP), total bilirubin (T-Bili), total protein (TP), albumin (Alb), A/G ratio, total cholesterol (T-Chol), triglycerides (TG), blood urea nitrogen (BUN), creatinine (Cr), glucose (Glu), and calcium (Ca), phosphorus (P) were measured. In addition, electrolyte analyzer (AVL9181, Roche, Germany) was used to measure chloride (Cl), sodium (Na), and potassium (K).

For autopsy, detail macroscopic inspection was conducted for organs and tissues of the entire bodies of all animals. All organs and tissues were removed and fixed in the 10% neutral buffered formalin from the autopsied animals for histopathological examination. Fixed organs and tissues were turned, dehydrated, and praffin embedded to make tissue sections. The tissue sections were cut into thin slices and stained with hematoxylin & eosin (H&E). The grey matters of the bone tissues were removed by Calci-Clear-RapidTM solution (National diagnostics, U.S.A.). The remained organs and tissues were kept in the 10% neutral buffered formalin. A local tolerance test was done at the injection site of all animals.

For statistical analyses, weight, hematological and blood biochemical examination results were tested by SAS (version 9.3, SAS Institute Inc., U.S.A.). Bartlett test was used for equal variance assumption (significance level at 0.05). When equal variance assumption was satisfied, one-way analysis of variance (ANOVA) was applied at the significance level 0.05. For post-hoc analysis, Dunnett's t-test was used (significance level at 0.05 or 0.01). When equal variance assumption was not satisfied, Kruskal-Wallis test was used (significance level 0.05) for testing the differences between groups.

2. Results
==========

There were no death cases in both gender control and WDP injection groups during the observation period ([Table 2](#t2-kpi-21-104){ref-type="table"}).

No abnormal general symptoms were observed in male and female control and WDP 0.125, and 0.25 mL/animal injection groups. Hematuria were detected in WDP 0.5 mL/animal injection group 30 minutes after the injection in 4 male rats and all of the female rats. However, from 1 hour after the injection, no abnormal symptoms were observed ([Table 3](#t3-kpi-21-104){ref-type="table"}, [4](#t4-kpi-21-104){ref-type="table"}).

During the observation period, there were no statistical significant differences in weight changes between WDP and control groups ([Figure 1](#f1-kpi-21-104){ref-type="fig"}, [2](#f2-kpi-21-104){ref-type="fig"}).

No meaningful changes in hematological parameters, such as RBC, HCT, MCH, MCHC, MCV, WBC, NEU, EOS, BASO, Reti, LYM, MONO, PT, and aPTT, were detected in both male and female WDP injection groups. Otherwise, changes in both HGB and PLT in male rates were non dose-dependent minor changes that did not have toxicity. No significant changes in blood biochemical parameters, such as ALT, AST, ALP, γ-GTP, T-Bili, TP, Alb, A/G ratio, T-Chol, TG, BUN, Cr, Glu, Ca, P, Cl, Na, and K, were observed in male and female WDP administration groups. Mild other changes were observed sporadically without dose-dependency. No macroscopic abnormal findings were detected in male and female WDP groups at macroscopic autopsy ([Table 5](#t5-kpi-21-104){ref-type="table"}). Topical resistance test at the injection area of both gender rats showed that there were no effects by the test materials. Other histopathological examination results showed that they were natural occurrence or accidental changes that were irrelevant with toxicity ([Table 6](#t6-kpi-21-104){ref-type="table"}).

3. Discussion
=============

DG contains decursin, α-pinene, limonene, decurisinol nodakenen, β-sistosterol, stigmasterol and so on ([@b3-kpi-21-104]) and includes both water-soluble ingredients and essential oil ([@b4-kpi-21-104]). DG enhance axonal regrowth by the induction of GAP-43 expression and retrograde transport of phospho-Erk1/2 protein from the injury site to the cell body after sciatic nerve injury ([@b21-kpi-21-104]). AGR can suppress the reactive gliosis which disturbs the astrocyte regeneration in the brain of the rat with cerebral infarction after MCAO by controlling the expression of CD81 and GFAP. The effect may be modulated by the up-regulation of c-Fos and ERK ([@b20-kpi-21-104]). AGR ethanol extract attenuate inflammation through inhibition of NO production and iNOS expression by blockade of NK-κB activation in LPS-stimulated RAW 264. Cells ([@b22-kpi-21-104]). AGR prevent formation of cystic follicles and malfunction of ovary in polycystic ovary rat ([@b23-kpi-21-104]). AGR evaluates the collagenase and tyrosinase activity and reduce the metalloproteinase-1(MMP-1) activity (anti-MMP-1) ([@b24-kpi-21-104]). So DG has a wide range of therapeutic applications because DG can have potential as anti-aging, nerve-protecting, and anti-polycystic ovary ingredient in addition to have the effect to tonify and activate of blood and the effect of anti-inflammation and anti-platelet. DGP also has a wide range of application. DGP research only reports on the anti- inflammatory effect ([@b25-kpi-21-104]), so further various research is needed. DGP, which contains essential oils, is a possibility to be turn sour without being absorbed under the skin. Therefore, WDP has been developed to maximize the effects of essential oils and water-soluble ingredients, and the essential oil component has been developed to facilitate absorption in the body ([@b4-kpi-21-104]). Pharmacopuncture is divided into an intramuscular injection into the acupuncture point and a vascular injection into the vein according to the insertion method. In general, the method of intramuscular injection takes up a large part ([@b1-kpi-21-104]). However, vascular injections are used to achieve difficult or rapid effects of oral administration of herbal medicines. MGP among vascular injection pharmacopunctures, that is intravenous injection pharmacopuncture (IIP), are representative, and it is mainly used for anti-cancer therapy in clinical practice ([@b26-kpi-21-104]). In China, since 1940, IIP has been developed and applied in various ways. In Korea, in addition to MGP, we have been working on the development of IIP such as daebohwalryeok pharmcopuncture ([@b2-kpi-21-104]), water-soluble ginseng pharmacopuncture ([@b19-kpi-21-104]), Gamisoyo-san pharmcopuncture ([@b27-kpi-21-104]), Water-soluble Carthami-flos pharmacopuncture ([@b28-kpi-21-104]), and Saeng Maek San pharmacopuncture ([@b29-kpi-21-104]). WDP is also highly likely to be developed as IIP. However, IIP requires efficacy, but its safety is very important. We performed single-dose toxicity test to evaluate safety of WDP intravenous administration at first. The results of toxicity test showed that hematuria was detected in WDP 0.5 mL/animal injection group 30 minutes after the injection in 4 male rats and all of the female rats, but not was observed from 1 hour after the injection. Slight changes of male and female WDP administration groups in blood biochemical examination were not considered to be toxic because of sporadic observations without dose-dependency. This single-dose toxicity test has shown that WDP does not have toxic effects. Further a long-tern toxicity test, such as a 4-week, repeated-dose, toxicity test, and pharmacological test should be conducted.

Conclusion
==========

WDP single dose intravenous injection results showed that WDP have no toxic effects and a lethal dose of WDP should be over 0.5 mL/animal in male and female rats under the study condition. So WDP may be safe.
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###### 

Grouping of the animals

  Group                 Injection dose (mL/animal)   Number of animals   
  --------------------- ---------------------------- ------------------- ---
  G1: Control group     0.5 (saline)                 5                   5
  G2: Low-dose group    0.125 (WDP)                  5                   5
  G3: Mid-dose group    0.25 (WDP)                   5                   5
  G4: High-dose group   0.5 (WDP)                    5                   5

WDP: Water-soluble Danggui pharmacopuncture

###### 

Summary of Mortality

  Sex      Group/Dose (mL/animal)   No. of animals   Days after dosing   Mortality                                                       
  -------- ------------------------ ---------------- ------------------- ----------- --- --- --- --- --- --- --- --- --- --- --- --- --- -----------
  Male     G1 (saline)              5                0                   0           0   0   0   0   0   0   0   0   0   0   0   0   0   0/5 (0/5)
           0                                                                                                                             
           G2 (WDP)                 5                0                   0           0   0   0   0   0   0   0   0   0   0   0   0   0   0/5 (0/5)
           0.125                                                                                                                         
           G3 (WDP)                 5                0                   0           0   0   0   0   0   0   0   0   0   0   0   0   0   0/5 (0/5)
           0.25                                                                                                                          
           G4 (WDP)                 5                0                   0           0   0   0   0   0   0   0   0   0   0   0   0   0   0/5 (0/5)
           0.5                                                                                                                           
                                                                                                                                         
  Female   G1 (saline)              5                0                   0           0   0   0   0   0   0   0   0   0   0   0   0   0   0/5 (0/5)
           0                                                                                                                             
           G2 (WDP)                 5                0                   0           0   0   0   0   0   0   0   0   0   0   0   0   0   0/5 (0/5)
           0.125                                                                                                                         
           G3 (WDP)                 5                0                   0           0   0   0   0   0   0   0   0   0   0   0   0   0   0/5 (0/5)
           0.25                                                                                                                          
           G4 (WDP)                 5                0                   0           0   0   0   0   0   0   0   0   0   0   0   0   0   0/5 (0/5)
           0.5                                                                                                                           

WDP: Water-soluble Danggui pharmacopuncture

###### 

Summary of Clinical Signs by hours after dosing

  Sex      Group/Dose (mL/animal)   No. of animals   Clinical sign   Hours (Day 0) after dosing               
  -------- ------------------------ ---------------- --------------- ---------------------------- --- --- --- ---
  Male     G1 (saline)              5                NOA             5                            5   5   5   5
           0                                                                                                  
           G2 (WDP)                 5                NOA             5                            5   5   5   5
           0.125                                                                                              
           G3 (WDP)                 5                NOA             5                            5   5   5   5
           0.25                                                                                               
           G4 (WDP)                 5                NOA             1                            5   5   5   5
           0.5                                       Hematuria       4                                        
                                                                                                              
  Female   G1 (saline)              5                NOA             5                            5   5   5   5
           0                                                                                                  
           G2 (WDP)                 5                NOA             5                            5   5   5   5
           0.125                                                                                              
           G3 (WDP)                 5                NOA             5                            5   5   5   5
           0.25                                                                                               
           G4 (WDP)                 5                NOA                                          5   5   5   5
           0.5                                       Hematuria       5                                        

NOA: [N]{.ul}o [O]{.ul}bservable [A]{.ul}bnormality, WDP: Water-soluble Danggui pharmacopuncture

###### 

Summary of Clinical Signs by hours after dosing

  Sex      Group/Dose (mL/animal)   No. of animals   Clinical sign   Days after dosing                                                   
  -------- ------------------------ ---------------- --------------- ------------------- --- --- --- --- --- --- --- --- --- --- --- --- ---
  Male     G1 (saline)              5                NOA             5                   5   5   5   5   5   5   5   5   5   5   5   5   5
           0                                                                                                                             
           G2 (WDP)                 5                NOA             5                   5   5   5   5   5   5   5   5   5   5   5   5   5
           0.125                                                                                                                         
           G3 (WDP)                 5                NOA             5                   5   5   5   5   5   5   5   5   5   5   5   5   5
           0.25                                                                                                                          
           G4 (WDP)                 5                NOA             5                   5   5   5   5   5   5   5   5   5   5   5   5   5
           0.5                                                                                                                           
                                                                                                                                         
  Female   G1 (saline)              5                NOA             5                   5   5   5   5   5   5   5   5   5   5   5   5   5
           0                                                                                                                             
           G2 (WDP)                 5                NOA             5                   5   5   5   5   5   5   5   5   5   5   5   5   5
           0.125                                                                                                                         
           G3 (WDP)                 5                NOA             5                   5   5   5   5   5   5   5   5   5   5   5   5   5
           0.25                                                                                                                          
           G4 (WDP)                 5                NOA             5                   5   5   5   5   5   5   5   5   5   5   5   5   5
           0.5                                                                                                                           

NOA: [N]{.ul}o [O]{.ul}bservable [A]{.ul}bnormality, WDP: Water-soluble Danggui pharmacopunctiire

###### 

Summary of Clinical Signs by hours after dosing

  Sex                     Male   Female                                    
  ----------------------- ------ -------- ------ ----- ---- ------- ------ -----
  Group                   G1     G2       G3     G4    G1   G2      G3     G4
  Dose (mL/animal)        0      0.125    0.25   0.5   0    0.125   0.25   0.5
  No. of animals          5      5        5      5     5    5       5      5
                                                                           
  Unremarkable findings   5      5        5      5     5    5       5      5
  no, of examined         5      5        5      5     5    5       5      5

External surface and all organs in body cavity were remarkable.

###### 

Summary of Histopathological Findings

  ------------------ --------------------- ----------------- ------- ------ ----- ---
  Organ/Findings     Sex                                     Male                 
                                                                                  
  Group/                                   G1                G2      G3     G4    
  Dose (mL/animal)                         0                 0.125   0.25   0.5   
  No. of animals                           5                 5       5      5     
                                                                                  
  Injection site     Remarkable findings   No. of examined   0       0      0     0
                                                             5       5      5     5
  ------------------ --------------------- ----------------- ------- ------ ----- ---

  ------------------ ------------------------------------------- ----------------- -------- ------ ----- ---
  Organ/Findings     Sex                                                           Female                
                                                                                                         
  Group/                                                         G1                G2       G3     G4    
  Dose (mL/animal)                                               0                 0.125    0.25   0.5   
  No. of animals                                                 5                 5        5      5     
                                                                                                         
  Injection site     \- Cell infiltration, inflammatory, focal   ±                 0        1      0     0
                     \- Crust, epidermis                         ±                 0        0      0     1
                                                                 No. of examined   5        5      5     5
  ------------------ ------------------------------------------- ----------------- -------- ------ ----- ---

Grade- ±: minimal
